Investor's Business Daily on MSN1h
Sarepta Plunges After EMA Puts Gene Therapy Studies On Hold Following Teen's Death
Sarepta stock plunged Thursday after European officials put all studies of the company's gene therapy, Elevidys, on hold.
Scientists granted $420,000 to test gene therapy for rare neurological disease
Childhood-onset striatonigral degeneration is a rare genetic disorder that robs children of the ability to walk and speak by ...
Fierce Pharma18h
For struggling cell and gene therapy field, Peter Marks' FDA exit adds even more uncertainty
The sudden resignation of Peter Marks, M.D., Ph.D., from the FDA branch that regulates biological products for humans ...
CRISPR gene editing breakthrough eliminates 50% of head, neck tumors
Head and neck cancers often begin in the mouth, throat, or voice box. They're among the most common cancers in the world, ...
Gene therapy loses luster as investors eye quicker returns from weight-loss drugs
Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing early investors to ...
pharmaphorum2h
Germany will reimburse haemophilia gene therapy Hemgenix
The agreement with the GKV-Spitzenverband – the national association of statutory health insurance funds – means that ...
The American Journal of Managed Care1h
How to Manage Costs of Novel Cellular, Gene Therapies: Laura Bobolts, PharmD, BCOP
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth, discusses strategies for managing costs of novel cellular and gene therapies in the oncology pipeline.
11 Best Gene Therapy Stocks to Buy According to Analysts
Here is our list of the 11 Best Gene Therapy Stocks to Buy According to Analysts.
Fierce Pharma23h
Gene therapy CDMO Artis BioSolutions launches with acquisition of Landmark Bio
Out of the shadows, new CDMO Artis BioSolutions has decloaked on a mission to tackle the tricky production process for ...
STAT9dOpinion
Impatient about cell and gene therapy? Progress in biotech is not always linear
The arc of biotechnology is one of breakthroughs and struggles, writes Tim Hunt, CEO of the Alliance for Regenerative ...
Fierce Biotech1d
Atsena raises $150M for ocular gene therapies with Bain, Sofinnova in tow
The $150 million will also go toward Atsena’s preclinical pipeline and expand the use of the biotech’s spreading AAV.SPR ...
Medera Presented Updated Results from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at 2025 HFpEF Summit
Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing ...